Business Description
IN8bio is a New York-based clinical-stage company working to develop cancer and autoimmune disease treatments using a specialized type of immune cell called gamma-delta T cells. The company has several therapies in active clinical trials, including treatments for brain cancer and blood cancers, with additional programs at earlier stages of research. Founded in 2016 and formerly known as Incysus Therapeutics, IN8bio is working to advance its pipeline from early-stage research through to potential commercialization.
